Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2006 1
2017 2
2018 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study.
Rodziewicz M, Dyball S, Lunt M, McDonald S, Sutton E, Parker B, Bruce IN; British Isles Lupus Assessment Group Biologics Register (BILAG-BR) consortium. Rodziewicz M, et al. Lancet Rheumatol. 2023 May;5(5):e284-e292. doi: 10.1016/S2665-9913(23)00091-7. Lancet Rheumatol. 2023. PMID: 38251591 Free article.
Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity.
Yee CS, Farewell V, Isenberg DA, Prabu A, Sokoll K, Teh LS, Rahman A, Bruce IN, Griffiths B, Akil M, McHugh N, D'Cruz D, Khamashta MA, Bowman S, Maddison P, Zoma A, Allen E, Gordon C; British Isles Lupus Assessment Group. Yee CS, et al. Arthritis Rheum. 2006 Oct;54(10):3300-5. doi: 10.1002/art.22162. Arthritis Rheum. 2006. PMID: 17009266 Free article.
Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register.
McCarthy EM, Sutton E, Nesbit S, White J, Parker B, Jayne D, Griffiths B, Isenberg DA, Rahman A, Gordon C, D'Cruz DP, Rhodes B, Lanyon P, Vital EM, Yee CS, Edwards CJ, Teh LS, Akil M, McHugh NJ, Zoma A, Bruce IN; British Isles Lupus Assessment Group Biologics Register. McCarthy EM, et al. Rheumatology (Oxford). 2018 Mar 1;57(3):470-479. doi: 10.1093/rheumatology/kex395. Rheumatology (Oxford). 2018. PMID: 29216396 Free PMC article.
Deconvolution of whole blood transcriptomics identifies changes in immune cell composition in patients with systemic lupus erythematosus (SLE) treated with mycophenolate mofetil.
Akthar M, Nair N, Carter LM, Vital EM, Sutton E, McHugh N; British Isles Lupus Assessment Group Biologics Register (BILAG BR) Consortium; MASTERPLANS Consortium; Bruce IN, Reynolds JA. Akthar M, et al. Arthritis Res Ther. 2023 Jun 30;25(1):111. doi: 10.1186/s13075-023-03089-5. Arthritis Res Ther. 2023. PMID: 37391799 Free PMC article.
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.
McCarthy EM, Sutton E, Nesbit S, Parker B, Jayne D, Griffiths B, Isenberg DA, Rahman A, Gordon C, D'Cruz DP, Rhodes B, Lanyon P, Vital EM, Yee CS, Edwards CJ, Teh LS, Akil M, McHugh NJ, Zoma A, Bruce IN; British Isles Lupus Assessment Group Biologics Register. McCarthy EM, et al. Rheumatology (Oxford). 2017 Jun 1;56(6):1041-1043. doi: 10.1093/rheumatology/kex044. Rheumatology (Oxford). 2017. PMID: 28431104 Free PMC article. No abstract available.
Correction: Deconvolution of whole blood transcriptomics identifies changes in immune cell composition in patients with systemic lupus erythematosus (SLE) treated with mycophenolate mofetil.
Akthar M, Nair N, Carter LM, Vital EM, Sutton E, McHugh N; British Isles Lupus Assessment Group Biologics Register (BILAG BR) Consortium; MASTERPLANS Consortium; Bruce IN, Reynolds JA. Akthar M, et al. Arthritis Res Ther. 2023 Sep 4;25(1):160. doi: 10.1186/s13075-023-03160-1. Arthritis Res Ther. 2023. PMID: 37667347 Free PMC article. No abstract available.
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.
McCarthy EM, Sutton E, Nesbit S, Parker B, Jayne D, Griffiths B, Isenberg DA, Rahman A, Gordon C, D'Cruz DP, Rhodes B, Lanyon P, Vital EM, Yee CS, Edwards CJ, Teh LS, Akil M, McHugh NJ, Zoma A, Bruce IN; British Isles Lupus Assessment Group Biologics Register. McCarthy EM, et al. Rheumatology (Oxford). 2017 Jun 1;56(6):1049. doi: 10.1093/rheumatology/kex218. Rheumatology (Oxford). 2017. PMID: 28549192 Free PMC article. No abstract available.